RUNX2/CBFB modulates the response to MEK inhibitors through activation of receptor tyrosine kinases in KRAS-mutant colorectal cancer

Intrinsic and acquired resistances are major hurdles preventing the effective use of MEK inhibitors for treatment of colorectal cancer (CRC). Some 35–45% of colorectal cancers are KRAS-mutant and their treatment remains challenging as these cancers are refractory to MEK inhibitor treatment, because...

Descripción completa

Detalles Bibliográficos
Autores principales: Šuštić, Tonći, Bosdriesz, Evert, van Wageningen, Sake, Wessels, Lodewyk F.A., Bernards, René
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2019
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6931198/
https://www.ncbi.nlm.nih.gov/pubmed/31865182
http://dx.doi.org/10.1016/j.tranon.2019.10.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6931198/
https://www.ncbi.nlm.nih.gov/pubmed/31865182
http://dx.doi.org/10.1016/j.tranon.2019.10.006

Ejemplares similares